ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP) today reported financial results for the second quarter ended June 30, 2026.
"The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. "CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our in vivo pipeline with the initiation of Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline."
Read more at globenewswire.com
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)
/A%20close-up%20of%20the%20Broadcom%20logo%20on%20a%20smartphone%20by%20Timon%20via%20Adobe%20Stock.jpeg)
